Advertisement

Topics

Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st

16:06 EDT 20 Mar 2017 | PR Newswire
This article has expired, however you can still download the PDF.
Preview:
MENLO PARK, Calif., March 20, 2017 /PRNewswire/ -- Forty Seven Inc., a clinical-stage immuno-oncology company announced today that Mark A. McCamish, M.D., Ph.D., will join the company on May 1 as President and CEO.  Dr. McCamish, who was mos...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...